Moderna (MRNA) Stock Dips While Market Gains: Key Facts

In the latest trading session, Moderna (MRNA) closed at $49.20, marking a -1.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.11%. On the other hand, the Dow registered a loss of 0.13%, and the technology-centric Nasdaq increased by 0.18%.

Heading into today, shares of the biotechnology company had lost 13.44% over the past month, lagging the Medical sector's loss of 6.43% and the S&P 500's loss of 4.28%.

Investors will be eagerly watching for the performance of Moderna in its upcoming earnings disclosure. On that day, Moderna is projected to report earnings of -$2.03 per share, which would represent year-over-year growth of 19.44%. Alongside, our most recent consensus estimate is anticipating revenue of $229.96 million, indicating a 112.92% upward movement from the same quarter last year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of -$6.8 per share and a revenue of $2.08 billion, signifying shifts of +6.34% and +7.12%, respectively, from the last year.

Investors might also notice recent changes to analyst estimates for Moderna. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 1.69% fall in the Zacks Consensus EPS estimate. Moderna currently has a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 145, finds itself in the bottom 41% echelons of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Moderna, Inc. (MRNA): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research